Ethanol Impurity Analysis Using the Agilent Cary 3500 Flexible UV-Vis Spectrophotometer

Significance of the topic

Ultraviolet–visible (UV‑Vis) spectroscopy is a routine, nondestructive analytical technique widely applied in pharmaceutical quality control (QC) for rapid detection and qualification of low‑level impurities. Ethanol is extensively used in pharmaceutical manufacturing as a solvent, disinfectant and preservative; its purity must meet pharmacopeial criteria (USP, EP, JP) to assure drug safety and product quality. The pharmacopeias require sensitive UV absorbance testing using long optical path lengths to detect trace UV‑active impurities, making instrument performance, path length flexibility, and software automation critical for routine QC workflows.

Objectives and study overview

This application note demonstrates a validated workflow for pharmacopeial ethanol impurity testing using the Agilent Cary 3500 Flexible UV‑Vis spectrophotometer equipped with a variable long‑path‑length holder and Cary UV Workstation software. The goals were to: (i) show compliance with USP/EP/JP impurity absorbance limits using a 50 mm cell, (ii) compare two commercially available undenatured ethanol samples (100% and 96%), and (iii) illustrate how instrument hardware and software features streamline routine analyses and reporting.

Methodology

Key methodological elements:

• Sample preparation: Each sample and the blank (Milli‑Q water) were dispensed as 17 mL into Agilent 50 mm rectangular quartz cuvettes and capped to limit evaporation.
• Spectral acquisition: Scans were recorded from 235 to 340 nm with 1.0 nm interval, 2.0 nm spectral bandwidth, and 0.1 s signal averaging per point.
• Path length: A 50 mm path length was used to meet pharmacopeial sensitivity requirements for low absorbance impurities.
• Data processing: Cary UV Workstation software's end‑of‑sequence analysis and a customizable calculator automatically located maximum absorbances in pharmacopeial wavelength bands and compared them to acceptance criteria.

Used instrumentation

Instrumentation and accessories employed in the study:

• Agilent Cary 3500 Flexible UV‑Vis spectrophotometer (xenon flash lamp source, research‑grade photometric performance).
• Variable long‑path‑length cell holder configured at 50 mm (toolless adjustment with indexed notches allowing 20, 40, 50, 100 mm reproducibly).
• Rectangular quartz cuvettes, 50 mm path (Agilent part number 6610016100).
• Cary UV Workstation software with end‑of‑sequence analysis, customizable calculators, method saving and OpenLab integration for secure data handling and regulatory compliance.

Main results and discussion

Pharmacopeial acceptance limits used (per USP/EP/JP): maximum absorbance not exceeding 0.40 at 240 nm, 0.30 between 250–260 nm, and 0.10 between 270–340 nm.

Results summary:

• 100% undenatured ethanol: Spectrum was a smooth, monotonically decreasing curve with no obvious peaks or shoulders, indicating only trace UV‑active impurities. The sample met two of three pharmacopeial absorbance criteria but exceeded the 0.40 limit at 240 nm and therefore did not pass the monograph acceptance criteria.
• 96% undenatured ethanol: The sample passed all three absorbance criteria despite a small bump observed in the 260–290 nm region. The bump remained below the acceptance thresholds and was interpreted as trace impurities acceptable for pharmaceutical use.

Discussion points:

• Use of a 50 mm path length increased sensitivity for low‑level UV‑absorbing impurities in accordance with the pharmacopeias. This longer path length follows Beer‑Lambert behaviour and improves detectability relative to standard 10 mm cells.
• The smooth spectral shapes and absence of pronounced shoulders suggest that detected absorbances represent trace impurity content rather than gross contamination or sample degradation.
• Automated end‑of‑sequence calculations reduced operator variability, ensured consistent application of the acceptance windows and facilitated rapid go/no‑go decisions for QC.

Benefits and practical applications of the method

The combination of the Cary 3500 hardware and Cary UV Workstation software delivers practical advantages for pharmaceutical QC labs:

• Pharmacopeia compatibility: Supports USP <857>, Ph. Eur. 2.2.25 and JP 2.24 workflows with built‑in or customizable calculations.
• Improved sensitivity: Variable long‑path‑length capability (up to 100 mm) allows optimization of absorbance signals for low‑level impurities without complex alignment.
• Operational efficiency: Tool‑free holder indexing and software method storage speed routine testing and reduce setup errors.
• Data integrity and compliance: OpenLab integration, audit trails and automated report generation (PDF/CSV) support 21 CFR Part 11 and EU Annex 11 requirements for secure, traceable recordkeeping.
• Reduced maintenance and sustainability: Xenon flash lamp removes daily warm‑up delays, reduces replacement frequency and is backed by a 10‑year replacement warranty; the instrument has sustainability credentials (third‑party recognition).

Future trends and applications

Anticipated developments and opportunities based on the demonstrated workflow:

• Greater automation and LIMS connectivity to enable high‑throughput, fully traceable QC pipelines and remote monitoring of routine assays.
• Expanded use of variable long‑path cells for other low‑absorbance analytes and impurity assays currently limited by sensitivity in standard cuvettes.
• Integration with chemometric tools and spectral libraries to improve impurity profiling and help discriminate between acceptable trace impurities and problematic contaminants.
• Enhanced sustainability and total cost‑of‑ownership considerations driving adoption of long‑lived lamp technologies and instruments complying with green‑lab standards.
• Potential for hybrid workflows combining UV‑Vis screening with orthogonal techniques (e.g., GC‑MS or LC‑MS) for targeted identification when UV features are observed near acceptance limits.

Conclusion

The Agilent Cary 3500 Flexible UV‑Vis spectrophotometer, when configured with a variable long‑path‑length holder and paired with Cary UV Workstation software, provides a robust, compliant and efficient solution for pharmacopeial ethanol impurity testing. The 50 mm path length enhanced sensitivity required by USP/EP/JP monographs; automated analysis and reporting simplified routine decision making and supported regulatory data integrity. In the demonstrated comparison, 96% undenatured ethanol met pharmacopoeial UV‑absorbance criteria while the 100% sample exceeded the 240 nm limit and therefore failed the monograph acceptance test.

References

1. Agilent Technologies. Effortlessly Change Path Length to Enhance Photometric Performance; technical overview, publication number 5994‑5781EN, 2023.
2. Pure Chemistry. Ethanol in Pharmaceutical Manufacturing (99.9% Purity); informational resource.
3. United States Pharmacopeia. Alcohol. USP–NF Monographs; DOI: 10.31003/USPNF_M1238_05_01.
4. European Directorate for the Quality of Medicines & HealthCare. Ethanol 96%. European Pharmacopoeia, 12th ed.; Strasbourg, 2025; monograph 1317.
5. Ministry of Health, Labour and Welfare. Ethanol. Japanese Pharmacopoeia, 18th ed.; Tokyo, 2021; p 964.
6. Agilent Technologies. Data Integrity Options for GMP Facilities; flyer, publication number 5994‑0740EN, 2022.
7. Agilent Technologies. Pharmaceutical Analysis Using UV‑Vis: Compliance with USP Chapter <857>, and European Pharmacopoeia (Ph. Eur. Chapter 2.2.25); application note, publication number 5994‑1188EN, 2020.